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Abstract The objective of the study was to develop and
validate a practical prognostic index for patients with
amyotrophic lateral scleroses (ALS) using information
available at the first clinical consultation. We interrogated
datasets generated from two population-based projects
(based in the Republic of Ireland and Italy). The Irish pa-
tient cohort was divided into Training and Test sub-co-
horts. Kaplan–Meier methods and Cox proportional
hazards regression were used to identify significant pre-
dictors of prognoses in the Training set. Using a weighted
grading system, a prognostic index was derived that
separated three risk groups. The validity of index was
tested in the Irish Test sub-cohort and externally confirmed
in the Italian replication cohort. In the Training sub-cohort
(n = 117), significant predictors of prognoses were site of
disease onset (HR = 1.7, p = 0.012); ALSFRS-R slope
prior to first evaluation (HR = 2.8, p\ 0.0001), and ex-
ecutive dysfunction (HR = 2.11, p = 0.001). The risk
group system generated using these results predicted me-
dian survival time in the Training set, the Test set (n = 87)
and the Italian cohort (n = 122) with no overlap of the
95 % CI (p\ 0.0001). In the validation cohorts, a high-
risk classification was associated with a positive predictive
value for poor prognosis of 73.3–85.7 % and a negative
predictive value (NPV) for good prognosis of 93.3–100 %.
Classification into the low-risk group was associated with
an NPV for bad prognosis of 100 %. A simple algorithm
using variables that can be gathered at first patient en-
counter, validated in an independent patient series, reliably
predicts prognoses in ALS patients.
Keywords Amyotrophic lateral scleroses  Motor neuron
disease  Population-based  Prognoses
Introduction
Amyotrophic lateral scleroses (ALS) is a neurodegen-
erative disorder characterised by upper and lower motor
neuron degeneration and ultimately death from respiratory
failure. The rate of disease progression among patients is
highly variable [1]. The identification of the key factors
that can influence outcome is important for effective timing
of medical interventions and for appropriate stratification
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Previously reported negative prognostic indicators in
ALS include older age of onset, bulbar onset of disease,
and short delay to diagnosis [3]. Cognitive impairment,
particularly executive dysfunction, has also been shown to
be associated with worse prognosis [4, 5]. However, a
universally accepted prognostic model that can be utilised
in a clinical setting has yet to be established.
The aim of this study was to develop a reliable prog-
nostic model in ALS using information that can be gath-
ered at the first patient encounter, by interrogation of
detailed datasets derived from two population-based stud-
ies of ALS.
Methods
The development of the prognostic index and internal
validation was carried out in a population-based sample of
Irish ALS patients while the external validation of the in-
dex was undertaken in a population-based cohort of Italian
ALS patients.
The Irish data were generated as part of a large-scale
population-based study of cognitive function in incident
patients with ALS, performed between October 2006 and
February 2011. Details of the population-based Irish ALS
Register and study methodology have been previously
published [6–8]. In brief, the inclusion criterion was a di-
agnosis of possible, probable or definite ALS according to
the Revised El Escorial criteria [9]. Exclusion criteria were
confined to conditions that could affect neuropsychological
function, such as major hemispheric stroke or alcohol de-
pendence syndrome. All clinical and neuropsychological
data were gathered during home-visits and patients were
followed prospectively from diagnosis to time of death.
The Italian cohort comprised a sample of incident pa-
tients (n = 122) from a population-based study of cogni-
tion undertaken in the provinces of Torino and Cuneo of
Piemonte region [10]. All patients were diagnosed between
1 January 2009 and 31 December 2011 with definite,
probable and probable laboratory-supported ALS accord-
ing to the revised El Escorial and were identified through
the Piemonte and Valle d’Aosta register for ALS [11].
Exclusion criteria, previously published, were neurological
conditions that can affect cognition [10].
Disease severity in both studies was estimated using the
Revised ALS Functional Rating Scale (ALSFRS-R) [12]. A
retrospective estimate of the average rate of functional
decline prior to time of first evaluation was computed by
dividing the difference between the ALSFRS-R scores
obtained by the patient and a presumed normal score (48
points) at symptom onset by disease duration (in months) at
time of evaluation. This measure is termed the ALSFRS-R-
based linear estimate of rate of disease progression [13].
For the sake of simplicity we will refer to it from here
onward as the ALSFRS-R slope.
All patients underwent comprehensive neuropsycho-
logical assessments [6, 10]. Three executive tasks were
selected from each database to evaluate executive dys-
function. The choice of tasks was based on the available
literature, including the Irish dataset, regarding the tasks’
sensitivity to executive dysfunction in this patient popula-
tion. Tasks used to evaluate executive function in the Irish
cohort were the Stroop Colour–Word Interference task
[14], verbal fluency (phonemic verbal fluency index and
semantic fluency) [15], and the backward digit span. Nor-
mative data were generated using a large cohort (n = 136)
of age, sex and education-matched healthy controls. Tasks
used to evaluate executive function in the Italian cohort
were the Stroop Interference Colour–Word task [14], ver-
bal fluency (FAS phonemic fluency) and the Trail making
A and B test and normative data were generated using
Italian age, sex, and education-matched controls
(n = 127). In both cohorts, executive dysfunction was
defined as a score that is two standard deviations below that
of the corresponding control mean on at least two of the
three selected tasks.
Patients with established ALS-causing mutations were
identified using either targeted next-generation sequencing,
or repeat-primed PCR [16, 17].
Statistical analysis
To formulate and test the prognostic index, a three-stage
process was carried out.
The Irish cohortwas split randomly into two sub-cohorts: a
Training and a Test sub-cohort comprising approximately 60
and 40 % of the cohort, respectively. Baseline characteristics
of the two sub-cohortswere compared using two-sample t test
or Mann–Whitney U test depending on whether the variable
displayed normal distribution or not. The Chi-square test was
used for comparing proportions, withMonte Carlo correction
where appropriate.
Data from the Training sub-cohort were used to identify
significant predictors of prognosis and generate the prog-
nostic index and prognostic classification system. Survival
time (in months) was computed from date of symptom
onset to time of death from all causes. Potential predictors
were selected based on the available literature and the
likelihood of availability at first clinical assessment. Vari-
ables that had a significant effect on survival on univariate
analyses were included in multivariate analyses. In the case
of categorical variables, univariate analyses were carried
out using Kaplan–Meier survival methods and the log-rank
test was used to test equality of outcome. Cox proportional
hazards regression analyses were undertaken in case of
continuous variables and for building multivariate models
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(after ensuring that the assumption of proportional hazards
was not violated). Patients who were alive at the time of
analysis were censored. After identifying significant pre-
dictors of prognosis on multivariate analyses, internal
validation of the model was carried out using boot-strap-
ping techniques using 1000 random samples to obtain 95 %
confidence.
Based on the results of the survival analyses, the prog-
nostic index was generated by assigning weighted scores to
each factor (higher scores for worse prognoses) guided by
the hazard ratio (HR) suggested by the multivariate Cox
proportional model. Continuous variables with significant
survival effects on both univariate and multivariate ana-
lysis were converted to categorical variables to allow easier
formulation of the prognostic index. Patients were then
classified into risk groups based on total index score, with
higher scores predicted to be associated with worse
outcome.
Lastly, the classification system was tested in the Irish
Test sub-cohort (internal validation) and the Italian cohort
(external validation). This was carried out using Kaplan–
Meier method estimated median survival times and by
comparing the proportion of patients from each prognostic
risk group who had either (1) poor prognosis, defined as
survival time of 25 months or less from symptom onset or
(2) good prognosis, defined as survival time of at least
50 months or more from symptom onset.
All tests were two-tailed and statistical significance was
set at p\ 0.05. Statistical analyses were carried out using
SPSS version 21 (SPSS Inc. Chicago, Illinois).
Written informed consent was obtained from all par-
ticipants. The Irish study has full ethical approval from
Beaumont Hospital Research Ethics Committee while the
Italian study has full ethical approval from the San Gio-
vanni Hospital of Turin Ethics Committee.
Results
The Irish population-based cohort represented 61.6 % of
patients diagnosed with ALS in the Republic of Ireland
during the set study period (244/396). Forty patients were
subsequently excluded, and the remaining 204 patients
were included in the final study. Reasons for non-capture
included death prior to contact (n = 95) and patients de-
clining participation (n = 47) or not responding to invita-
tion (n = 10). Reasons for exclusion included history of
major hemispheric stroke (n = 9), alcohol dependence
syndrome (n = 6), pre-morbid learning disability (n = 1),
major psychiatric disorder (n = 3), atypical disease course
suggestive of variant (n = 4), severe active epilepsy
(n = 1), patients being too sick to participate adequately in
the study (n = 12), patient not fully informed of diagnosis
(n = 1) and co-morbid Alzheimer’s disease at baseline
(n = 3).
Recruited ALS patients displayed no significant differ-
ences with regard to age, sex distribution, or site of onset
when compared to patients who were diagnosed in the
same period but did not participate in the study, although
non-participants experienced a shorter median survival
time (p\ 0.0001).
At time of analysis (May 2014), 177 of the 204 patients
in the Irish cohort were deceased (86.8 %). Median sur-
vival time from symptom onset of the deceased patients
was 32 months (range 7–126, interquartile range = 21).
Among patients who remained alive (n = 27) the median
follow-up time was 47 months from study enrolment, and
median follow-up time measured from symptom onset was
75 months (range 51–114).
There were no significant differences in baseline char-
acteristic between the two Irish sub-cohorts (Training and
Test groups, see Table 1).
Table 1 Baseline
characteristics of the two Irish
sub-cohorts (the training and
test sets) and the Italian
validation cohort
Irish cohort p value Italian cohort
Training set Testing set
N 117 87 122
Mean age at symptom onset (SD) 60.8 (10.3) 62.7 (10.4) 0.351 65.6 (10.5)
Males 61.5 % 55.2 % 0.441 58.2 %
Mean education in years (SD) 12.0 (3.4) 12.3 (3.0) 0.528 9.1 (4.2)
Site of onset
Spinal 65.5 % 57.0 % 0.353 63.9 %
Bulbar 33.6 % 40.7 % 36.1 %
Respiratory 0.9 % 2.3 % 0.0 %
Median delay to diagnosis (months) 10.0 12.0 0.444 8
Median disease duration (months) 17.0 19.0 0.652 10
Mean ALSFRS-R (SD) 35.7 (7.9) 37.1 (7.0) 0.194 39.8 (5.8)
FH of ALS 12.0 % 13.8 % 0.861 8.1 %
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Data from the Training sub-cohort were used to identify
significant predictors of survival time. Univariate survival
analysis was carried out for the following clinical vari-
ables: age at symptom onset, gender, site of disease onset
(spinal-onset versus non-spinal or bulbar/respiratory onset),
diagnostic category as per the El Escorial (possible, prob-
able or definite), the ALSFRS-R slope (48-ALSFRS-R/
disease duration at time assessment), the presence (versus
absence) of family history of ALS and/or frontotemporal
lobar degeneration in a 1st or 2nd degree relative, and the
presence (versus absence) of executive dysfunction on
cognitive testing.
Factors associated with significantly worse prognosis on
univariate analyses in the Training sub-cohort (n = 117)
were (1) Bulbar or respiratory (i.e. non-spinal) onset of
disease with a median time of 30 months (95 % CI
26.9–33.1, SE 1.6) compared to 36 months in patients with
spinal-onset disease (95 % CI 30.9–41.4, SE 2.6,
p = 0.032); (2) higher ALSFRS-R slope (indicating faster
functional decline), HR 2.6, 95 % CI 1.9–3.5, SE 0.15,
p\ 0.0001; (3) and the presence of executive dysfunction
(median survival = 27 months, 95 % CI 19.9–34.1, SE
3.6) as opposed to absence of executive dysfunction (me-
dian survival time 37 months, 95 % CI 28.2–45.8,
SE = 4.5, p\ 0.000).
Although patients with older age at symptom onset and
female patients tended to have shorter survival, the effect
did not reach statistical significance in either case
(p = 0.094 and p = 0.064, respectively). Similarly, a
positive family history for ALS and/or FTLD and El Es-
corial diagnostic category at diagnosis had no significant
effect on survival on univariate analyses (p = 0.972 and
p = 0.109, respectively).
Proportional hazards Cox regression was used to build a
multivariate model that included site of disease onset,
ALSFRS-R slope, and executive dysfunction (n = 117).
The survival effect of all the three factors persisted on
multivariate analyses: (1) non-spinal onset of disease,
HR = 1.7 (95 % CI 1.12–2.63, SE 0.22, p = 0.012); (2)
ALSFRS-R slope: HR = 2.8 (95 % 2.00–3.81,
SE = 0.166, p\ 0.0001); and executive dysfunction:
HR = 2.11 (95 % 1.37–3.28, SE = 0.233, p = 0.001).
Internal validation of the model was carried out using boot-
strapping techniques. Based on the results of 1000 ran-
domly generated samples, the robustness of the three-pa-
rameter model was confirmed.
Based on these results a simple prognostic index, named
the ALS Prognostic Index (or API), was generated (Fig. 1)
with possible scores ranging from zero to six (higher scores
indicating worse predicted prognosis). The figure also
shows how patients were then divided using the total API
score into three risk groups, termed the ALS risk groups.
The index and prognostic risk group classification pro-
cedure were applied to the Irish Training set. The index and
classification were also applied to the Irish Test sub-cohort
(after excluding one patient for missing data precluding full
classification, n = 86) and, for external validation pur-
poses, to the Italian cohort (n = 122).
As shown in Table 2, in all three cohorts the ALS risk
groups predicted survival time (log-rank test p\ 0.0001 in
all three cohorts) with no overlap of the 95 % confidence
intervals (Kaplan–Meier survival plots for validation co-
horts shown in Fig. 2).
To investigate the utility of the ALS risk group classi-
fication in predicting risk of (1) poor prognosis, defined as
death within 25 months of symptom onset and (2) good
Fig. 1 This figure illustrates
how to calculate of the ALS
Prognostic Index for individual
patients and how to allocate
patients to the ALS risk groups
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prognosis, defined as survival time of at least 50 months
post-symptom onset, we included only patients who were
either deceased at time of analyses or whose follow-up
time measured from symptom onset was at least 50 months
(all Irish patients and 91 Italian patients). In all three co-
horts, the API risk group was a reliable predictor of both
poor and good prognosis (Fig. 3a, b, Chi-square test
p\ 0.0001 in all cases). In the validation cohorts, classi-
fying a patient into a high-risk group was associated with a
positive predictive value for poor prognosis of
73.3–85.7 % and a negative predictive value for having
good prognosis was 93.3–100 %. Conversely, the low-risk
group was associated with a positive predictive value for
good prognosis of 59.1–60.1 % and negative predictive
value for bad prognosis of 100 %.
As the ALSFRS-R slope was the strongest predictor of
survival in the model, we investigated the utility of a
Table 2 This table summarises the Kaplan–Meier estimated median survival time for the three ALS risk groups in the Irish training and test
cohorts and the Italian cohort




95 % CI N Median
survival time
95 % CI N Median
survival time
95 % CI
Training set 26 22.0 16.0–28.0 64 34.0 30.5–37.5 27 63.0 50.1–75.9 \0.0001
Irish test set 14 11.0 7.3–14.7 51 33.0 28.6–37.4 21 73.0 48.0–98.0 \0.0001
Italian cohort 18 22.0 19.2–24.8 72 35.0 26.9–43.1 32 91.0 63.6–118.4 \0.0001
Fig. 2 Figure shows Kaplan–Meier plots for survival probabilities in
the Irish test cohort (a) and Italian cohort (b). In all cases ALS
patients were stratified by ALS prognostic risk group. Dashed line
low-risk group, dotted line medium-risk group, and solid line high-
risk group
Fig. 3 This figure illustrates proportion of patients in each cohort
stratified by API risk group who a died within 25 months of symptom
and b had a survival time of 50 months or more
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classification system based on this measure only (ALSFRS-
R slope \0.025 points/month, 0.25–0.49 points/month,
0.50–0.99 points/month, and C1 points/months). As shown
in Table 3 and Fig. 4, although this model was useful in the
Irish validation cohort with only minor overlap of survival
times, it was poor predictor of survival in the Italian cohort
(external validation cohort).
Risk groups and genetic status
We investigated the relationship of the risk group alloca-
tion and the C9orf72 pathogenic hexanucleotide repeat in
both populations. Genetic screening for common ALS ge-
netic mutation was undertaken in 197 Irish patients
(96.6 % of the cohort). TARDP gene and FUS gene mu-
tations were identified in one patient each (0.5 % of cohort
in each case) and 19 patients carried the C9orf72 hexanu-
cleotide repeat expansion (9.3 %).
Carriers of the C9orf72 repeat expansion represented
10.6 % of the medium-risk group and 13.2 % of the high-
risk groups compared to 4.4 % of the low-risk group,
although the difference did not reach statistical
significance.
In the Italian cohort genetic status was available in all
122 cases, with TARDP gene mutation identified in 5 cases,
FUS and optineurin in 1 case each. Three patients carried
the C9orf72 repeat expansion (2.6 %) with two cases in the
Medium Risk and 1 case in the High risk, representing 2.8
and 5.6 % of each group, respectively, and no C9orf72
positive cases in the low-risk group.
Discussion
Heterogeneity of disease progression in ALS is a major
confounder of clinical trials, and a validated, reliable and
practical prognostic model for ALS patients is urgently
required [18]. Accurate prognostic stratification also has
pragmatic implications for the management of individual
patients, such as feeding tube placement, end-of-life deci-
sions, putting supportive services in place, timely referral
for palliative care [19]. However, a reliable model that can
be used in a clinical setting model has remained elusive.
Proposed models to date have been excessively complex to
allow practical use in the setting of a busy clinic or a
Table 3 This table summarises
the Kaplan–Meier estimated
median survival time for the
patients in the Irish test cohorts
and the Italian cohort classified
by ALSFRS-R slope only
ALSFRS-R slope (points/month) Irish test set Italian cohort
N Median
survival
95 % CI N Median
survival
95 % CI
\0.25 14 79.0 66.4–91.6 18 78.0 28.3–127.7
0.25–0.45 21 45.0 31.6–58.3 31 43.0 23.5–63.5
0.50–0.99 36 36.0 27.3–36.7 40 35.0 27.3–42.7
C1.0 16 16.0 27.3–36.7 33 28.0 4.1–51.5
Log rank p value \0.0001 0.004
Fig. 4 Figure shows Kaplan–Meier plots for survival probabilities in
the Irish test cohort (a) and Italian cohort (b). In all cases ALS
patients were stratified by ALSFRS-R slope only. Solid line ALSFRS-
R slope of 1.0 points/month or more, dotted line ALSFRS-R slope
0.50–0.99 points/month, dashed line ALSFRS-R slope 0.25–0.49
points/month, dash and dot line ALSFRS-R slope \0.25
points/month
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clinical trial centre and, to our knowledge none has been
validated using more than one population [20–24].
This study has utilised data-led hypothesis-free analyses
of prospectively gathered population-based data to gener-
ate a simple predictive model. The objective was to for-
mulate a model using clinical and neuropsychological data
that can be gathered at first evaluation of the patient that
can reliably identify those with poor prognosis. External
validation was carried out using independently gathered
data from a different population.
Our data support the utility of retrospective computation
of the rate functional motor decline prior to first evaluation
an estimate of disease progression rates in individual pa-
tients [13]. Similarly, the association of bulbar and respi-
ratory onset of disease with poorer prognosis has also been
previously described [3, 25, 26], and probably reflects the
earlier presentation of swallowing and respiratory diffi-
culties in these patients.
Our study now incorporates for the first time cognitive
status into a prognostic model. We and others have already
shown that executive dysfunction is predictive poor prog-
nosis [5, 10, 27]. However, full assessment of cognitive
status remains a challenge. We have estimated that the total
time required to perform the tasks included in this study is
approximately 30–40 min. As standardised clinic-based
screening tools to assess cognitive and behavioural status
are now available [28, 29], it would be desirable to repli-
cate our findings using these tools.
Previously published prognostic models have reported
conflicting data regarding the reliability of prognostic
factors such age, gender, El Escorial diagnostic category
[1, 3, 20, 21, 26, 30–32]. Environmental factors such as
smoking, socio-economic status, marital status, and mul-
tidisciplinary care have also been reported to affect prog-
nosis in ALS [26, 32, 33]. Findings relating to the effect of
gender on survival have been inconsistent, with a sig-
nificant protective effect for males observed more fre-
quently in retrospective studies compared to prospective
population-based studies [3, 26, 34–36]. In our study, the
trends for older age of onset and female gender did not
reach statistical significance, and inclusion of these of
variables in our multivariate model made no difference to
the overall results (data not shown).
Genetic data, though available, was not used in our
prognostic model because our aim was to incorporate
variables that can be obtained on first patient encounter.
Reviewing the risk group distribution among patients car-
rying the C9orf72 pathogenic hexanucleotide repeat in both
populations revealed that this mutation was rare among
patients categorised as Low risk. This is consistent with
previous reports from our group and other groups sug-
gesting worse prognoses in this group and it suggests the
patients with atypical long survival times are likely to
harbour either no mutation or a new yet to be identified
gene mutation.
The limitations of this study include its retrospective
nature. Although the data were collected prospectively, the
design of the study included extensive cognitive testing,
and did not prioritise body mass index or forced vital ca-
pacity, as many of the patient assessments were conducted
in patients’ homes to maximise recruitment. In addition,
patients with particularly aggressive disease are less likely
to be recruited to cognitive studies. However, this effect is
unlikely to be large in this study as the cohorts from both
centres were population-based and data were gathered by
home-visits in both studies.
In conclusion, we have shown that information gathered
on first patent visit can be used to reliably predict prog-
nosis. This prognostic algorithm is more reliable than that
predicted by ALSFRS slope alone, and is sufficiently
simple to enable its use by clinicians in busy clinics for
individual patient prognostication. In addition, the sim-
plicity and reliability of the model has the potential to
improve stratification protocols in future clinical trials.
Notwithstanding the fact that we have validated the algo-
rithm in two populations, prospective studies replicating
our findings using brief cognitive screening tools such as
the ECAS are also desirable.
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